ABSTRACT Introduction: P53 and bcl-2 over expression was reported to affect the biology and prognosis of patients endometrial carcinoma. Methods: This prospective study included 38 patients with histologically confirmed endometrial carcinoma and staged clinically as stage I. Immunohistochemical staining of the tumor specimens obtained by dilatation and curettage (D&C) with P53 and bcl-2 monoclonal antibodies was done. The surgical, pathological and follow up data of all patients were studied. Results: There were 18 cases (47.4%) with positive P53 over expression. P53 over expression was found to be associated with increasing grade of differentiation, advanced stage, and non endometrioid type (significant), and increased depth of myometrial invasion (non-significant). It was associated with more recurrence rate (22% versus 15%) and shorter mean survival time (33.9 versus 29.2 months). Bcl-2 expression was present in24 cases (63.2%) of the studied group. There was significant decrease in bcl-2expression with poorly differentiated, advanced stage, increased depth of myometrial invasion, and non-endometrioid type. It was not significantly correlated with recurrence rate and mean survival time. Conclusion: P53 over expression in the D&C specimens was associated with adverse surgicopathological criteria, increased mortality rate, and shorter survival time in patients with endometrial carcinoma. A significant decrease in bcl-2 expression was associated with adverse surgicopathological criteria, but it was not significantly correlated with prognosis of the patients.
Cite this paper
nullFyallah, E. , Hemida, R. , Anwar, K. , Nadia, N. , Sherif, L. and Sayed-Ahmed, M. (2011) Preoperative evaluation of P53 and bcl-2 over expression in clinical stage 1 endometrial carcinoma and their correlation with surgico-pathological data and prognosis of patients. Open Journal of Obstetrics and Gynecology, 1, 55-63. doi: 10.4236/ojog.2011.12012.
 Jamel, A., Thomas, A. and Murray, T. (2002) Cancer statistics. Cancer Journal for Clinicians, 52, 23-57.
Mariani, A., Sebo, T.J., Katzmann, J.A., Rocke, P.C., Koeney, C.L., Lesnick, T.G. and Podratz, K.C. (2005) Endometrial cancer: Can nodal status be predicted with curettage? Gynecologic Oncology, 96, 594-600.
Osmangaolu, M.A., Kadiglu, S. and Bozkaya, H. (2005) The relationship between mutant P53 gene, DNA contents and conventional clinico-pathological prognostic variable in cases with endometrial carcinoma. European Journal of Gynecological Oncology, 26, 64-70.
Petros, A.M., John, J., Huang, Q., Nettesheim, D., Van Dyk, L.F., Labrada, L., Speck, S.H., Levine, B., Olejniczak, E.T. and Virgin, H.W. (2005) A surface groove essential for viral bcl-2 function during chronic infection. Plos Pathology, 1, 10.
Mano, Y., Kikushi Yamamoto, K., Kita, T., Hirata, J. and Tode, T. (1999) Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer. European Journal of Cancer, 35, 1214-1219.
Kapucouglu, N., Aktepe, F., Kaya, H., Biracan, S., Karahan, N. and Cris, M. (2007) Immuno-histochemical expression of PTN in normal, hyperplastic and malignant endometrium and its correlation with hormone receptors, bcl-2, bax and apoptotic index. Pathology Research Practice, 203, 153-162. doi:10.1016/j.prp.2007.01.003
Ohkoushi, T., Sakuragi, N., Watari, H., Nomura, E. and Tolo, Y. (2002) Prognostic significance of bcl-2 over expression and lymph node metastasis in surgically staged endometrial carcinoma. American Journal of Obstetrics & Gynecology, 187, 353-359.
Creasman, W.T., De Geest, K., Disaia, P.J. and Zaino, R.J. (1999) Significance of true surgical pathologic staging. A Gynecologic Oncology Group Study. American Journal of Obstetrics & Gynecology, 181, 31-34.
Pilka, R., Mickova, I., Lubusky, M., Duskova, M., Ricankova, M. and Kudela, M. (2008) Expression of P53, Ki 67, bcl-2, C-erb 2, estrogen and progesterone receptors in endometrial cancer. Ceská Gynekologie, 73, 222- 227.
Simionescu, C., Georgescu, C.V., Magaritescu, C., Bata, S., Marinescu, M., Enachescu, V. and Patnu, E. (2006) P53 and PCNA immunoexpression in endometrial carcinomas. Romanian Journal of Morphology and Embryology, 97, 137-141.
Appel, M.L., Edelweiss, M.I., Flek, J., Rivore, W.A., Monego, H.I. and Dos Reis, R. (2008) P53 and bcl-2 as prognostic markers in endometrial carcinoma. Pathology & Oncology Research, 14, 23-30.
Veralucia, L.B. and Liliana, A.L. (2003) P53, estrogen and progesterone receptors in diagnostic curettage for endometrial adenocarcinoma and their correlation with morphological data and disease stage at hysterectomy. Sao Paulo Medical Journal, 12, 163-166.
Nicola, R., Simone, F., Federico, P., Barbara, M., Franco, G., Marina, G. and Ezio, F. (2005) The association between P53 expression, stage and histological feature in endometrial cancer. European Journal of Gynecological Oncology, 123, 111-116.
Marcia, L.M., Appel Maria, I., Edelweiss, J. F., Luis, F., Heleusa, I. and Ricordo, R. (2008) P53 and bcl-2 as prognostic markers in endometrial carcinoma. Pathology & Oncology Research, 14, 23-30.
Erkanli, S., Eren, F., Pekin, S. and Bagis, T. (2004) Bcl-2 and P53 expression in endometrial carcinoma. Journal of Experimental and Clinical Cancer Research, 23, 97-103.
Cerchi, P.L., Marras, V., Capobianco, G., Amborosini, G., Piga, M.D., Fadda, G.M., Rosas, N. and Dessole, S. (2001) Prognostic value of P53, C-erb-B2 and MIB-1 in endometrial carcinoma. European Journal of Gynecological Oncology, 22, 451-453.
Halperin, R., Zehavi, S., Habler, E. and Bukovsky, I. (2001) Comparative immunohistochemical study of endometroid and serous papillary carcinoma of the endometrium. European Journal of Gynecological Oncology, 22, 122-126.
Geisler, J.P., Geisler, H.E., Wiemann, M.C., Zhan, Z., Miller, G.A. and Crabtree, W. (1998) Lack of bcl-2 persistence: An independent prognostic indicator of poor prognosis in endometrial carcinoma. Gynecologic Oncology, 71, 305-307. doi:10.1006/gyno.1998.5192
Fanning, J., Brown, S., Phibbs, G., Kramer, T. and Zaher, A. (2002) Immunohistochemical evaluation is not prognostic for recurrence in fully staged high-risk endometrial cancer. International Journal of Gynecological Cancer, 12, 286-289.